Turmoil in the management level has no doubt created a big uncertainty of the company, hence the SP has been hammered heavily in recent months.
There are also many reports predicting the formular shortage in US will be over from this Spring.
We had 2 of the above bad news and a silent new management team.
Would be nice for the company to shift back to Chinese market focus strategy, although diversifying to US is a great move.
AT the end of the day Chinese are buying more of our products than American do.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
-0.005(3.13%) |
Mkt cap ! $138.4M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.3¢ | $367.7K | 2.372M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 481529 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 187880 | 11 |
View Market Depth
| Last trade - 15.51pm 31/07/2025 (20 minute delay) ? |
| BUB (ASX) Chart |